For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

And now, research shows that tenecteplase works just as well as the standard clot-busting drug alteplase used to treat ...

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a decades-old medication used by most hospitals in the U.S. and could hold ...

Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly ...

Thrombolysis has been the mainstay of reperfusion therapy for ischemic stroke for 30 years. Alteplase, a recombinant form of tissue plasminogen activator, has been the sole thrombolytic treatment ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase ...